Roger Newton, PhD, FAHA, is currently Founder, Executive Chairman and Chief Scientific Officer of Esperion Therapeutics, Inc., and is a fellow of the American Heart Association. Prior to founding Esperion in 2008, Roger was Senior Vice President, Pfizer Global R&D from 2004 to 2008. Previously, Roger was Co-founder, President & CEO of the original Esperion from July 1998 until its acquisition by Pfizer in 2004 for $1.3 B. Prior to founding the original Esperion, Roger was Chairman of the Atherosclerosis Drug Discovery Team at Warner Lambert from 1981 to 1993, during which he co-discovered and was the product champion of
Lipitor. From 1994 to 1998, he was a Distinguished Research Fellow, during which time he was actively involved in the preparation of the Lipitor NDA and the eventual worldwide product launch.
Roger is a director of a number of life science companies including Juventas Therapeutics, Inc. and Rubicon Genomics, Inc. and is also a member of the Technology Advisory Boards for Arboretum Ventures. In addition, he is also a member of the National Advisory Boards for the Life Science Institute and Cardiovascular Center at the University of Michigan. Roger earned a Ph.D. in Nutrition from the University of California, Davis, an M.S. in Nutritional Biochemistry from the University of Connecticut, and a B.S. in Biology from Lafayette College.